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ABSTRACT
While the epidermal growth factor receptor (EGFR)–mediated signaling pathway has been shown to have vital roles in many
developmental and pathologic processes, its functions in the development and homeostasis of the skeletal system has been poorly
defined. To address its in vivo role, we constructed transgenic and pharmacologic mouse models and used peripheral quantitative
computed tomography (pQCT), micro–computed tomography (mCT) and histomorphometry to analyze their trabecular and cortical
bone phenotypes. We initially deleted the EGFR in preosteoblasts/osteoblasts using a Cre/loxP system (Col-Cre Egfr
f/f), but no bone
phenotype was observed because of incomplete deletion of the Egfr genomic locus. To further reduce the remaining osteoblastic EGFR
activity, we introduced an EGFR dominant-negative allele, Wa5, and generated Col-Cre Egfr
Wa5/f mice. At 3 and 7 months of age, both
male and female mice exhibited a remarkable decrease in tibial trabecular bone mass with abnormalities in trabecular number and
thickness. Histologic analyses revealed decreases inosteoblast numberand mineralization activity and an increase in osteoclast number.
Significant increases in trabecular pattern factor and structural model index indicate that trabecular microarchitecture was altered. The
femurs of these mice were shorter and smaller with reduced cortical area and periosteal perimeter. Moreover, colony-forming unit–
fibroblast(CFU-F)assayindicatesthatthesemicehadfewerbonemarrowmesenchymalstemcellsandcommittedprogenitors. Similarly,
administration of an EGFR inhibitor into wild-type mice caused a significant reduction in trabecular bone volume. In contrast, Egfr
Dsk5/þ
mice with a constitutively active EGFR allele displayed increases in trabecular and cortical bone content. Taken together, these data
demonstrate that the EGFR signaling pathway is an important bone regulator and that it primarily plays an anabolic role in bone
metabolism.  2011 American Society for Bone and Mineral Research.
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Introduction
T
he epidermal growth factor receptor (EGFR) is a 170-kDa
glycoproteinonthecellsurfaceofavarietyofcelltypesandis
characterized by its ligand-dependent tyrosine kinase activity.
The EGFR, also known as Her1 or ErbB1, is closely related to three
other receptors, Her2 (ErbB2), Her3 (ErbB3), and Her4 (ErbB4).
Thesereceptorsarecomposedofanextracellular ligand–binding
domain with cystein-rich regions, a transmembrane domain, and
an intracellular domain with tyrosine kinase activity. EGFR binds
to a family of EGF-like ligands, including EGF, amphiregulin, and
transforming growth factor a (TGF-a), heparin binding EGF (HB-
EGF), betacellulin (BTC), and epiregulin. After ligand binding to
the extracellular domain, the EGFRs are activated by homo- or
heterodimerization with auto- and transphosphorylation on
tyrosine residues at the intracellular domain, and then a variety
of signaling pathways, such as Ras-Raf-MAP-kinase and PI-3-
kinase-Akt, are activated to influence cell behaviors, such as
proliferation, differentiation, apoptosis, and migration (reviewed
in ref. 1). Owing to its critical role in tumorigenesis, two classes of
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1022drugs, monoclonal antibodies (mAbs) and tyrosine kinase
inhibitors (TKIs), have been developed to target this receptor.
While mAbs target the extracellular ligand–binding domain of
EGFR and promote its internalization, TKIs block EGFR activity
by competing with adenosine triphosphate (ATP) for binding
to the receptor’s kinase pocket. Three TKIs, gefitinib from
AstraZeneca, erlotinib from OSI Pharmaceuticals, and lapatinib
from GlaxoSmithKline, have received regulatory approval for use
in cancer patients.
(2)
While the EGFR-mediated signaling pathway has been shown
to have a vital role in a variety of developmental and pathologic
processes, its function in the development and homeostasis of
the skeletal system has been poorly defined. Over the past
several years, research from our laboratory and others suggests
that EGFR signaling plays an important role in bone metabolism
by affecting both bone formation and bone resorption. EGF and
HB-EGFare potent mitogens for bone marrow stromal stem cells,
the progenitor cells for osteoblasts.
(3,4) Amphiregulin strongly
stimulates the proliferation of preosteoblastic cells.
(5) However,
all EGF-like ligands greatly inhibit osteoblast differentiation in an
EGFR-dependent pathway.
(5,6) Moreover, they suppress gene
expressionofosteoblastic markers,such asalkalinephosphatase,
bone sialoprotein (BSP), and osteocalcin, and the osteoblastic-
specific transcription factors Runx2 and osterix.
(6)
EGFR signaling also participates in bone resorption. EGF
and TGF-a have the ability to strongly stimulate bone resorption
in cultured fetal rat long bones, newborn mouse calvarial
cultures, and long-term human marrow cultures,
(7–9), suggesting
that these growth factors regulate osteoclastogenesis and
bone resorption. Previous studies in our laboratory delineated
the molecular mechanism of stimulation of bone resorption
by EGF-like ligands.
(10) We found that EGF-like ligands stimulate
osteoclastogenesis in an osteoblast/osteoclast coculture by
decreasing osteoblastic expression of osteoprotegerin (OPG),
a decoy receptor for the osteoclast determination factor,
receptor activator for nuclear factor kb ligand (RANKL),
and increasing osteoblastic expression of monocyte chemoat-
tractant protein 1 (MCP-1) but having no effect on RANKL
expression.
EGFR deficiency leads to early lethality at midgestation, birth,
or within 20 postnatal days depending on genetic background
owing to severe developmental abnormalities in placental,
neural, and epithelial tissues.
(11–13) A few surviving Egfr null pups
display craniofacial alterations and cleft palate.
(14) At birth, Egfr
null mice have delayed primary ossification of the cartilage
anlage, and trabecular bone formation is impaired.
(15) Mice
humanized for EGFR (the endogenous mouse Egfr gene was
replaced by human EGFR cDNA) exhibit low EGFR activity in
bone.
(16) They are growth retarded compared with wild-type
siblings, but no overt bone remodeling defects were observed at
birth. The most dramatic bone abnormality noted in these and
Egfr
–/– mice is the greatly enlarged hypertrophic chondrocyte
zoneinthe growth plate, suggestingthat EGFR mayplay arole in
chondrocyte terminal differentiation. By contrast, EGF-like ligand
knockout mice are viable and fertile, implying an overlapping
and compensating function among ligands. We have shown that
amphiregulin knockout mice have significantly less tibial
trabecular bone than wild-type siblings.
(5) Moreover, over-
expression of BTC ubiquitously results in a high cortical bone
mass phenotype that is EGFR-dependent.
(17)
In order to investigate the physiologic role of EGFR in bone
development and remodeling in adult animals, we constructed
three transgenic and pharmacologic mouse models with
modified EGFR activity and performed a detailed analysis of
their trabecular and cortical bone phenotypes in both sexes at
different ages. We conclude from our data that the EGFR
signaling pathway is an important bone regulator and that it
primarily plays an anabolic role in bone metabolism.
Materials and Methods
Transgenic mouse models
Egfr
f/f,
(18) Egfr
Wa5/þ,
(19) Egfr
Dsk5/þ,
(20) and Col 3.6-Cre
(21) mouse
strains were generated as described previously. Egfr
f/f has two
loxP sites flanking exon 3 of the EGFR. Deletion of exon 3
introduced a frameshift resulting in two stop codons in exon 4
and early termination of translation. Egfr
Wa5/þ mice on a 129S1/
SvImJ background were generated by breeding Egfr
Wa5/þ and
wild-type mice, and they were identified by their wavy hair
appearance. Egfr
Dsk5/þ mice on a 129S1/SvImJ background were
obtained by breeding Egfr
Dsk5/þ and wild-type mice. They were
identified by wavy hair, hyperpigmented footpads, and long
nails. To generate Col-Cre Egfr
f/f mice, we bred Col 3.6-Cre mice
with Egfr
f/f mice to obtain Col-Cre Egfr
f/þ mice. These mice then
were backcrossed with Egfr
f/f mice to generate Col-Cre Egfr
f/f
mice and their wild-type siblings. To generate Col-Cre Egfr
Wa5/f
mice, we bred Col 3.6-Cre mice with Egfr
Wa5/þ mice to obtain Col-
Cre Egfr
Wa5/þ mice. These mice then were crossed with Egfr
f/f
mice to generate Col-Cre Egfr
Wa5/f mice and their siblings, Col-Cre
Egfr
f/þ,Egfr
Wa5/f,andEgfr
f/þ.Col-CreEgfr
Wa5/fmicewereidentified
by their wavy coat appearance and polymerase chain reaction
(PCR) genotyping of the Cre gene using primers 5’-GAG TGA TGA
GGT TCG CAAGA-3’ and 5’-CTA CAC CAG AGA CGG AAATC-3’. All
work withanimals wasapproved by the Institutional Animal Care
and Use Committee (IACUC) at the University of Medicine and
Dentistry of New Jersey and the University of Pennsylvania.
EGFR inhibitor injection in mice
Four groups of 1-month-old female BALB/cAnNCr mice (National
Cancer Institute at Frederick, Frederick, MD, USA) with 10 mice
per group were treated with one of the following regimes: (1)
0.05% Tween-80, (2) 100mg/kg of gefitinib dissolved in 0.05%
Tween-80, (3) 0.5% methylcellulose, or (4) 50mg/kg of erlotinib
dissolved in 0.5% methylcellulose. All mice were treated daily
with oral gavage for a total of 40 days before hind limbs were
harvested for analysis. There was no significant difference in
body weight gain between control and treated groups. There
werenosignsofdehydration,lethargy,orataxiainanytreatment
group.
Peripheral quantitative computed tomography (pQCT)
analysis
The total and trabecular bone mineral density (BMD) values of
theproximaltibiaswereevaluatedexvivousinganXCTResearch
SA (Stratec Medizintechnik, Pforzheim, Germany). A scout scan
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1.4mmdistalfromtheproximalepiphysis.Thescanis1mmthick
with a voxel size of 90mm. Using an iterative algorithm, soft
tissue (density below 223mg/cm
3) was removed automatically.
The density of the remaining bone is reported as total density
(mg/cm
3). The outer 55% of the bone was peeled away in a
concentric fashion to determine trabecular density (mg/cm
3).
Cortical BMD was measured in the femur. The femur length was
determined after a 2D scout scan was run for the full length of
the bone. The pQCT scan was initiated at the mid-diaphysis of
the femur. The scan is 1mm thick with a voxel size of 90mm.
Using an iterative algorithm, tissue with density below 500mg/
cm
3 was removed automatically. The density of the remaining
bone is reported as cortical density (mg/cm
3).
Micro–computed tomography (mCT) measurement
The femurs and tibias were subjected to ex vivo mCT analyses
(Skyscan 1172 High-Resolution mCT; Skyscan, Antwerp, Belgium).
To study the trabecular architecture of the proximal tibial
metaphysis, a total of 160 slices with 5-mm resolution
corresponding to the volume from 0.3 to 1.1mm below the
growth platewerereconstructed andanalyzedusing3Danalysis.
To study the cortical bone parameters of the femoral midshaft, a
total of 160 slices with 5-mm resolution corresponding to the
volume from 2.2 to 3mm below the growth plate were
reconstructed and analyzed using 2D analysis.
Trabecular bone histomorphometry
Mice were injected subcutaneously with 25mg/kg of calcein
(Sigma-Aldrich, St Louis, MO, USA) at 9 and 2 days before
necropsy for dynamic histomorphometric measurements. Tibias
were dissected and processed for methyl methacrylate embed-
ding.Then 5-mmlongitudinalsectionswere cut usingaPolycut-S
motorized microtome (Reichert, Heidelberg, Germany) and
stained with Goldner’s trichrome. Unstained 10-mm sections
were used for dynamic measurements. Histomorphometric
measurements were performed in the proximal tibial meta-
physes in the area between 0.25 and 1.75mm below the growth
plate using the OsteoMeasure Analysis System (OsteoMetrics,
Inc., Decatur, GA, USA). The primary indices include the total
tissue area (TV), trabecular bone perimeter (BS), trabecular bone
area (BV), osteoblast surface, osteoblast number, osteoclast
surface, osteoclast number, osteoid surface, single- and double-
labeled surface, and interlabel width. The percentage of
osteoclast surface (OcS/BS), osteoid surface (OS/BS), osteoblast
surface (ObS/BS), mineralizing surface (MS/BS), mineral apposi-
tion rate (MAR, mm/d), and surface-referent bone-formation rate
(BFR/BS, mm
3/mm
2/yr) were calculated as described by Parfitt
and colleagues.
(22)
Mouse bone marrow osteoblastic culture and
colony-forming unit–fibroblast (CFU-F) assay
Bone marrow cells were flushed from femurs and tibias of 3-
month-old wild-type and Col-Cre Egfr
Wa5/f mice, filtered, and
seeded at 3 10
6cells per 35-mm dish for osteoblastic culture
and at 3 10
6cells per T-25 flask for CFU-F assay in a minimum
essential medium (a-MEM) supplemented with 15% fetal bovine
serum (FBS), 1% glutamine, 0.1% b-mercaptoethanol, 100IU/mL
of penicillin, and 100mg/mL of streptomycin. To obtained
osteoblastic culture, the medium were changed on day 5 with
the addition of 50mg/mL of L-ascorbic acid. On day 12, cells were
treatedwithEGF(50ng/mL)andharvestedattheindicatedtimes
for Western blot detection of total extracellular signal–regulated
kinases (ERKs) and phosphorylated ERKs. The antibodies were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). For CFU-F assays, cells were fixed and stained with methyl
violet on day 10. The number and diameter of colonies (each
containing more than 20cells) were counted and measured
microscopically.
Urinary deoxypyridinoline (DPD) analysis
Mice were housed in metabolic cages overnight, and urine
samples were collected the next morning. The DPD and
creatinine concentrations in the urine were determined by
MicroVue DPD and Creatinine ELISA kits (Quidel, San Diego, CA,
USA), respectively.
Statistical analysis
Because the relationship between bone structural and histo-
morphometric parameters and age is not linear, the effect of
genotype on pQCT, mCT, and histomorphometric data was
analyzed by independent Student’s t test assuming equal
variances at each age group. For all statistical analyses, a value of
p<.05 was considered significant. Animal number per group
varied from 8 to 16. All data are expressed as mean SEM.
Results
Col-Cre Egfr
f/f mice do not exhibit a bone phenotype
As a first step to examine the role of EGFR signaling in bone
developmentandremodeling,webredCol-CreandEgfr
f/fmiceto
generate preosteoblast and osteoblast-specific Egfr knockout
mice,Col-CreEgfr
f/f.Col3.6-Crecontainsa3.6-kbrata1(I)collagen
promoter–driven Cre and targets preosteoblasts and osteo-
blasts.
(21) It has been used successfully to knock down
preosteoblast/osteoblast expression in a number of mouse
models. Egfr
f/f mice were used previously to generate Egfr null
mice by crossing with mice carrying EIIa-Cre
(18) and skin-specific
Egfr knockout by crossing with K14-Cre transgenic mice.
(23) To
our surprise, Col-Cre Egfr
f/f mice did not exhibit any bone
phenotype at 1 and 3 months of age in both genders compared
with their wild-type siblings (Col-Cre Egfr
f/þ, Egfr
f/þ, and Egfr
f/f;
Supplemental Table S1). Genotyping Egfr alleles in mouse
calvarial osteoblastic cells harvested from these mouse pups
revealed that Cre expression did not completely convert Egfr
f to
Egfr
D, resulting in significant amounts of Egfr
f available to
express EGFR (Supplemental Fig. S1).
Trabecular bone phenotype of Col-Cre Egfr
Wa5/f
To overcome the preceding problem, we introduced the
antimorphic Wa5 allele into this system and generated Col-Cre
Egfr
Wa5/f mice. Wa5 has a single missense mutation Asp833Gly in
the highly conserved DFG domain of EGFR kinase catalytic loop
and codes for a kinase-dead dominant-negative receptor.
(19)
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are viable and do not exhibit any bone phenotype at 1 and
3 months of age in both genders (Supplemental Table S2). We
surmised that the presence of the Wa5 allele would further
reduce the remaining EGFR activity and result in a more
complete knockdown of EGFR activity in preosteoblast/osteo-
blast lineage cells. To confirm this, we cultured bone marrow
osteoblastic cells and treated them with EGF for 5, 15, and
30minutes. Since Ras-Raf-MAP-kinase is the major EGFR down-
stream signaling pathway,
(1) we performed Western blot analysis
to detect the phosphorylation of ERKs. As shown in Fig. 1, EGF
treatment stimulated a strong and sustained increase in the
amounts of phosphorylated ERK1 in cells derived from wild-type
mice, whereas it only induced ERK1 phosphorylation at
5minutes in cells derived from Col-Cre Egfr
Wa5/f mice, and this
induction was quickly diminished at 15 and 30minutes (Fig. 1).
Since,inthe following studies, the bonephenotype did notdiffer
between the three littermate control groups (Col-Cre Egfr
f/þ,
Egfr
Wa5/f, and Egfr
f/þ), all comparisons presented here are
between wild-type control groups (Col-Cre Egfr
f/þ and Egfr
f/þ)
and Col-Cre Egfr
Wa5/f mice. Mice among all four groups have
comparable body weight at all ages.
We first performed pQCT analysis to measure the total and
trabecular BMD values of the proximal tibias. As shown in Fig. 2,
there was no change in both BMD values between wild-type and
Col-Cre Egfr
Wa5/f miceat 1 monthof age, when the skeleton is still
immature and undergoing active modeling. However, when the
skeleton matured at 3 months of age, there were significant
decreases(12%to17%)intotalandtrabecularBMDvaluesinCol-
Cre Egfr
Wa5/f mice compared with wild-type mice in both
genders. A similar reduction in BMD value also was observed in
mice at 7 months of age. Next, mCT was used to quantitatively
access the structural parameters in the secondary spongiosa of
the trabecular compartment in the same bones. Initial imaging
suggestedthattherewassignificanttrabecularbonelossinadult
mice (Fig. 3A). Trabecular bone volume was considerably
decreased in the Col-Cre Egfr
Wa5/f mice by 20% to 40% compared
with control mice at 3 and 7 months of age (Fig. 3B). This was
mainly due to the reduction in trabecular number (Tb.N, 17% to
32%). We also observed a significant decrease in trabecular
thickness (Tb.Th, 10%) at 7 months of age and a nonsignificant
decrease at 3 months. A significant increase in trabecular
separation (Tb.Sp, 26%) was observed only in female mice at
3 months of age. Trabecular pattern factor (Tb.Pf) is an index for
trabecular bone connectivity, and the structure model index
(SMI) indicates the relative prevalence of rods and plates in the
trabecular bone. The strong increases in both Tb.Pf and SMI in
the Col-Cre Egfr
Wa5/f mice suggest that the structural integrity
and mechanical strength of the trabecular bone were compro-
mised in these EGFR-deficient animals.
Histomorphometric analyses of 7-month-old female Col-Cre
Egfr
Wa5/f mice further revealed the cellular mechanism under-
lying the trabecular bone changes (Fig. 4A). Compared with wild-
typemice,thesemiceexhibiteddramatic decreasesinosteoblast
surface (35%) and osteoblast number (35%), along with similar
decreases in osteoid surface (34%) and osteoid width (39%).
Furthermore, MAR and BFR were reduced about 15% and 24%,
respectively, whereas mineralizing surface (MS) remained
unaffected. In addition, there were marked increases in the
osteoclast surface (78%) and osteoclast number (78%). The
increaseof urinary DPDexcretion inCol-Cre Egfr
Wa5/f mice further
confirms the increase of bone resorption (Fig. 4B). The
combination of the decrease in bone formation and the increase
in bone resorption resulted in the dramatic loss of trabecular
bone volume and microstructural deterioration in the Col-Cre
Egfr
Wa5/f mice (Fig. 3).
Cortical bone phenotype of Col-Cre Egfr
Wa5/f
To assess the cortical bone phenotype of the Col-Cre
Egfr
Wa5/f mice, the femoral midshaft was examined by pQCT.
In comparison with wild-type mice, the femurs of the Col-Cre
Egfr
Wa5/f mice are 3% to 5% shorter in length in both genders
at 3 and 7 months of age (Table 1). While there were
insignificant decreases in cortical BMD, cortical thickness,
and endosteal perimeter, the cortical area and periosteal
perimeter were reduced significantly by about 11% and 7%,
respectively, in 3-month-old Col-Cre Egfr
Wa5/f mice. Furthermore,
mCT analysis of male mice confirmed these results and
demonstrated significant decreases in cortical area (18%,
p<.001), cortical thickness (14%, p<.001), periosteal perimeter
(7%, p<.01), and endosteal perimeter (7%, p¼.05) compared
Fig. 1. Mouse bone marrow osteoblastic cells derived from Col-Cre Egfr
Wa5/f mice exhibit decreased ERK phosphorylation in response to EGF, whereas
thosederivedfromEgfr
Dsk5/þmicehaveelevatedERKphosphorylation.(A)WesternblotsofphosphorylatedERK1/2(upperpanel)andtotalERK1/2(bottom
panel). Cells were harvested at the indicated times after 50ng/mL of EGF treatment. (B) The p-ERK1 level was quantified and normalized to total ERK1.
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(data not shown). No change was observed in cortical bone
porosity (data not shown). At 7 months of age, similar results
werealsoobtainedinmiceofbothgendersusingbothpQCTand
mCT (Table 1 and data not shown). Taken together, these data
suggest that deficiency in osteoblastic EGFR activity affects
cortical bone remodeling and results in smaller and thinner
femurs. Moreover, mCT images also revealed smaller and
thinner cortical bone in the tibial midshaft of Col-Cre Egfr
Wa5/f
mice (Fig. 3A).
Fig. 2. pQCT measurement of total and trabecular BMD of the proximal tibias of Col-Cre Egfr
Wa5/f mice and their wild-type (WT) siblings at 1, 3, and
7 months of age.
  p<.001;
 p<.01;
#p<.05.
Fig. 3. mCT scanning reveals that Col-Cre Egfr
Wa5/f mice are osteopenic. (A) mCT images of longitudinal sections of proximal tibias of 3- and 7-month-old
Col-Cre Egfr
Wa5/f and their wild-type (WT) siblings. (B) Structural parameters of trabecular bone in the proximal tibias. BV/TV¼trabecular bone volume/
tissue volume; Tb.Th¼trabecular thickness; Tb.Sp¼trabecular separation; Tb.N¼trabecular number; Tb.Pf¼trabecular pattern factor; SMI¼structure
model index.
  p<.001;
 p<.01;
#p<.05.
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Wa5/f mice have fewer bone marrow
mesenchymal stem cells (MSCs) and osteoprogenitors
HistomorphometrydatarevealedthatCol-CreEgfr
Wa5/fmicehave
less osteoblast surface, fewer osteoblast number, and less
osteoid surface, implying that bone marrow osteoprogenitors
might be affected in these mice. To analyze the mechanism, we
performed CFU-F assays to measure the number and prolif-
erative capacity of bone marrow MSCs and committed
osteoprogenitors from these mice. Specifically, we cultured
bonemarrowcellsingrowth mediumandmeasuredthe number
and size of CFU-F colonies. As shown in Fig. 5, we did not detect
Fig. 4. Bone formation and bone resorption are altered in Col-Cre Egfr
Wa5/f mice. (A) Static and dynamic bone histomorphometry of the proximal tibias of
7-month-old female mice. OBL¼osteoblast; OCL¼osteoclast; MS¼mineralizing surface; MAR¼mineral apposition rate; BFR¼bone-formation rate;
BS¼trabecular bone perimeter.
  p<.001;
 p<.01. (B) Urinary DPD assay. The DPD concentration was normalized to creatinine.
#p<.05.
Table 1. Cortical Parameters of the Femoral Midshaft of Col-Cre Egfr
Wa5/f Mice Measured by pQCT
Female Male
Wild type Col-Cre Egfr
Wa5/f Wild type Col-Cre Egfr
Wa5/f
3 months
Cortical BMD (mg/cm
3) 1073.8 7.6 1059.7 18.7 1111.2 9.9 1098.9 10.1
Cortical area (mm
2) 1.22 0.02 1.09 0.03
a 1.58 0.04 1.42 0.03
a
Cortical thickness (mm) 0.403 0.008 0.384 0.007 0.440 0.007 0.431 0.009
Periosteal perimeter (mm) 4.30 0.04 4.04 0.08
a 4.98 0.06 4.65 0.06
a
Endosteal perimeter (mm) 1.77 0.08 1.63 0.08 2.21 0.06 1.94 0.09
b
Length (cm) 1.57 0.012 1.53 0.02
b 1.62 0.01 1.56 0.01
a
7 months
Cortical BMD (mg/cm
3) 1196.2 9.5 1153.2 18.6 1195.0 10.5 1139.9 31.4
Cortical area (mm
2) 1.39 0.04 1.22 0.04
a 1.65 0.03 1.51 0.07
Cortical thickness (mm) 0.451 0.009 0.429 0.016 0.476 0.010 0.457 0.021
Periosteal perimeter (mm) 4.50 0.07 4.21 0.07
a 4.97 0.05 4.78 0.11
Endosteal perimeter (mm) 1.67 0.08 1.51 0.12 1.98 0.08 1.91 0.17
Length (cm) 1.61 0.02 1.53 0.02
b 1.64 0.01 1.55 0.01
a
ap<.005;
bp<.05 versus age- and sex- matched wild-type mice.
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from Col-Cre Egfr
Wa5/f mice in normal culture conditions.
Interestingly, when TGF-a (20ng/mL) was added to the cultures,
there were significant increases in colony number and size in
cellsfrom wild-typemice, indicatingthatnormalculturemedium
lacks sufficient amounts of the EGF ligands required for optimal
survival and proliferation of MSCs and osteoprogenitors on the
plastic surface. This is consistent with previous reports that
addition of EGF increases the CFU-F numbers when human
(24)
and mouse MSCs
(25) were cultured in medium supplemented
with FBS. However, similar increases in CFU-F number and size
were not observed in cells derived from Col-Cre Egfr
Wa5/f mice,
resulting significantly lower CFU-F number and smaller colony
size incellsfrom thesemicecomparedwiththose from wild-type
mice. These data clearly suggest that these mice have fewer
MSCs and osteoprogenitors and that the proliferative capacity of
these cells is also reduced.
EGFR inhibitors result in a bone phenotype similar to that
of genetically EGFR-deficient mice
Administration of EGFR inhibitors gefitinib or erlotinib into 1-
month-old wild-type mice for 6 weeks produced a significant
reduction in trabecular bone content compared with the
corresponding vehicle-treated mice. pQCT measurements of
the proximal tibial region showed (Fig. 6A) that total and
trabecularBMDdecreasedby11%to13%intheerlotinib-treated
animals and 23% to 28% in the gefitinib-treated animals
compared with their respective vehicle controls. mCT images
confirmed a more dramatic loss of trabecular bone in the
gefitinib-treatedmice(Fig.6B).Quantitativeanalysisshowedthat
trabecular bone content (BV/TV) decreased by 52% in gefitinib-
treated mice, which was attributed to a large decrease in Tb.N
(49%) and a moderate decrease in Tb.Th (5%) along with a
notable increase in Tb.Sp (38%; Fig. 6C). In elotinib-treated mice,
the loss of bone content was relatively moderate with an 18%
decreaseinBV/TV,accompaniedbyan11%increaseinTb.Spand
a 15% decrease in Tb.Th. Significant increases in Tb.Pf and SMI
with both inhibitors indicate a decrease in structural integrity
and deterioration in trabecular microarchitecture. The more
dramatic effects observed in gefitinib-treated mice are probably
due to the high dosage of gefitinib (100mg/kg/day versus
50mg/kg/day for erlotinib). We also noted similar changes in
trabecular bone structure in 3-month-old EGFR inhibitor–treated
mice (data not shown).
Similar to Col-Cre Egfr
Wa5/f mice, the trabecular bone loss in
gefitinib-treated mice is due to decreases in osteoblast (25%)
and osteoid surfaces (29%) and a dramatic increase in osteoclast
number (90%; Fig. 6D). Effects of the inhibitors also were
apparent in the femoral cortical compartment (Table 2), where
cortical BMD, cortical area and thickness, and periosteal and
endosteal perimeters exhibited a decreasing trend in inhibitor-
treated mice. Statistical significance was reached only for cortical
BMD and thickness of the gefitinib-treated mice.
The bone phenotype of Egfr
Dsk5/þ mice with high
EGFR activity
Dsk5 has a Leu863Gln mutation within a region of the kinase
domain important for stabilization of the receptor activation
loop, and therefore, the mutation is a gain-of-function allele that
causes increased EGFR signaling.
(20) Indeed, we observed an
increased basal level of ERK phosphorylation in osteoblastic cells
from these mice, and after EGF stimulation, the levels of
phosphorylated ERKs were much higher than those in cells from
wild-type mice (Fig. 1). Similar to Col-Cre Egfr
Wa5/f mice, Egfr
Dsk5/þ
mice showed no changes in BMD at 1 month of age (Fig. 7A).
However, when their skeleton matured at 3 months of age, both
female and male Egfr
Dsk5/þ mice had significantly increased
trabecular BMD values (12% and 15%, respectively; Fig. 7A), in
contrast to the bone loss phenotype of Col-Cre Egfr
Wa5/f mice
with low EGFR activity. The total BMD also was increased slightly,
although it only achieved statistical significance in females. At
6 months of age, the difference in BMD was less apparent in the
female mice, but male Egfr
Dsk5/þ mice still maintained higher
total (7%) and trabecular (11%) BMD values compared with their
wild-type siblings.
mCTimagesconfirmedtheincreaseinthetibialtrabeculararea
in Egfr
Dsk5/þ mice (Fig. 7B). The increase in bone content (BV/TV)
at 3 months of age (36% for female and 43% for male mice) was
accompanied by a major increase in Tb.N (28% to 35%), a slight
increase in Tb.Th (5%; Fig. 7C), and a moderate decrease in Tb.Sp
(9% to 17%). The significant reductions in Tb.Pf and SMI indicate
that trabecular microarchitecture was modified to have more
connectivity and healthier platelike structures in these mice.
These results are the opposite of the changes we observed with
Col-Cre Egfr
Wa5/f mice. Consistent with the pQCT data, female
Egfr
Dsk5/þ mice did not exhibit a bone phenotype at the age of 6
months, but male mice still showed a remarkable increase in
bone volume (49%) with similar changes in trabecular structural
parameters.
Histologic analysis revealed that the increase in trabecular
bone volume in Egfr
Dsk5/þ mice was due to changes in both bone
formation and bone resorption. In 3-month-old female Egfr
Dsk5/þ
mice, we observed a 37% increase in osteoblast surface, 35%
increase in unmineralized osteoid surface, 14% increase in MS,
18% increase in MAR, and 34% increase in BFR compared with
wild-type mice (Fig. 7D). Meanwhile, bone resorption was greatly
decreased, with a 27% reduction in osteoclast surface (Fig. 7D)
and a 22% decrease in urinary DPD concentration (p¼.059; Fig. 7E).
Fig. 5. Col-Cre Egfr
Wa5/f mice have fewer MSCs and committed osteo-
progenitors.Bonemarrowcellswereculturedin growthmediumwithout
(con) or with TGF-a (20ng/mL) for CFU-F assay. The number and size of
CFU-F colonies were counted microscopically.
 p<.05;
#p<.01.
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Col-Cre Egfr
Wa5/f mice.
There were significant changes in cortical bone structure at
the femur midshaft in both male and female Egfr
Dsk5/þ mice at
6 months of age (Table 3). We observed a significant increase
incorticalBMDinthefemalegroupandanonsignificantincrease
in the male group. This is due mainly to the 10% increase in
the cortical thickness. We also observed significant decreases in
both periosteal and endosteal perimeters (4% and 30%,
respectively).
Fig. 6. EGFR inhibitors decrease trabecular bone content. (A) pQCT measurement of total and trabecular BMD values of the proximal tibias of EGFR
inhibitor–treated mice. MC¼vehicle control for erlotinib treatment; Erl¼50mg/kg/day erlotinib treatment; T80¼vehicle control for gefitinib treatment;
Gef¼100mg/kg/day gefitinib treatment. (B) mCT images of longitudinal sections of proximal tibias. (C) mCT analysis of proximal tibias of EGFR inhibitor–
treated mice. (D) Static bone histomorphometric analysis in the same bone region.
  p<.001;
 p<.01;
#p<.05.
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MC Erlotinib T80 Gefitinib
Cortical BMD (mg/cm
3) 1002.2 10.2 985.9 13.3 1008.9 8.1 964.8 10.1
a
Cortical area (mm
2) 0.79 0.01 0.76 0.02 0.78 0.02 0.72 0.03
Cortical thickness (mm) 0.179 1.3 0.176 0.002 0.177 0.003 0.163 0.003
a
Periosteal perimeter (mm) 4.88 0.04 4.76 0.06 4.82 0.07 4.79 0.08
Endosteal perimeter (mm) 3.50 0.04 3.41 0.04 3.44 0.06 3.54 0.06
MC¼vehicle control for erlotinib treatment; Erlotinib¼50mg/kg/day; T80¼vehicle control for gefitinib treatment; Gefitinib¼100mg/kg/day.
ap<.05 versus corresponding vehicle.
Fig. 7. Egfr
Dsk5/þ mice with high EGFR activity have higher bone content. (A) pQCT analysis of total and trabecular BMD values of the proximal tibias of
Egfr
Dsk5/þ mice and their wild-type siblings at 1, 3, and 6 months of age. (B) mCT images of longitudinal sections of proximal tibias. (C) mCT analysis of
proximal tibias of Egfr
Dsk5/þ mice and their wild-type siblings. (D) Static and dynamic bone histomorphometric analyses of the proximal tibias of 3-month-
old female Egfr
Dsk5/þ mice. (E) Urinary DPD assay. p¼.059.
  p<.001;
 p<.01;
#p<.05.
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EGFR is extremely critical for embryonic development and
organogenesis, and therefore mice with systemic Egfr knockout
are either embryonic lethal or die shortly after birth owing to
placental defects and multiorgan abnormalities,
(13) making it
impossible to study the role of EGFR signaling in bone
development and remodeling postnatally. Nevertheless, a bone
phenotype was observed in several previous reports investigat-
ing either Egfr null mice at birth
(14,15) or transgenic mice
ubiquitously overexpressing its ligands, EGF
(26) or BTC,
(17) under
the control of ubiquitous actin promoters. Moreover, our
previous data found that amphiregulin null mice had less
trabecularboneat1monthofage.
(5)Thesefindingspromptedus
to study the in vivo role of EGFR in bone metabolism in adult
animals. To our knowledge, this is the first report demonstrating
that under physiologic conditions, abrogating EGFR activity in
osteoblasts results in an osteopenic phenotype in adult mice of
both sexes. Detailed analyses of bone structural parameters
by mCT revealed that trabecular bone loss in Col-Cre Egfr
Wa5/f
Fig. 7. (Continued)
Table 3. Cortical Parameters of the Femoral Midshaft of Egfr
Dsk5/þ Mice Measured by pQCT
Female Male
Wild type Egfr
Dsk5/þ Wild type Egfr
Dsk5/þ
3 months
Cortical BMD (mg/cm
3) 1087.3 8.8 1110.2 8.1 1137.5 12.3 1159.3 11.5
Cortical area (mm
2) 1.05 0.03 1.07 0.03 1.22 0.07 1.24 0.05
Cortical thickness (mm) 0.382 0.009 0.412 0.013 0.445 0.013 0.493 0.015
c
Periosteal perimeter (mm) 3.95 0.07 3.90 0.06 4.14 0.13 4.06 0.09
Endosteal perimeter (mm) 1.55 0.10 1.31 0.11 1.44 0.07 1.14 0.05
b
Length (cm) 1.52 0.01 1.50 0.01 1.56 0.02 1.55 0.01
6 months
Cortical BMD (mg/cm
3) 1183.4 9.0 1214.7 10.1
c 1189.5 9.2 1211.2 7.736
Cortical area (mm
2) 1.34 0.02 1.31 0.01 1.34 0.03 1.35 0.03
Cortical thickness (mm) 0.444 0.008 0.487 0.018
b 0.443 0.009 0.505 0.011
a
Periosteal perimeter (mm) 4.42 0.03 4.23 0.02
a 4.41 0.05 4.27 0.05
c
Endosteal perimeter (mm) 1.63 0.05 1.17 0.13
b 1.63 0.07 1.10 0.09
a
Length (cm) 1.63 0.01 1.62 0.01 1.57 0.01 1.60 0.01
b
ap<.001;
bp<.01;
cp<.05 versus age- and sex-matched wild-type mice.
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accompanied by deterioration of microachitecture, as evidenced
by increases in Tb.Pf and SMI. Furthermore, bone histomorpho-
metric studies demonstrated a significant decrease in bone
formation and an increase in bone resorption. Loss of EGFR
activity also affected the femoral cortical structure and resulted
in smaller and thinner cortical bone. Moreover, additional mouse
models with either a decrease or an increase in EGFR activity
(EGFR inhibitor–treated mice and Egfr
Dsk5/þ mice, respectively)
exhibited consistent bone phenotype changes. Taken together,
these data indicate that EGFR activity mainly plays an anabolic
role in bone development and remodeling.
To study the function of osteoblastic EGFR, we initially
generated Col-Cre Egfr
f/f mice, but surprisingly, no bone
abnormality was apparent in these mice. Dermo1-Cre targets
embryonic condensed mesenchyme, from which chondrocytes
and osteoblasts are derived.
(27) Similarly, dermo1-Cre Egfr
f/f mice
exhibitnormalbones(datanotshown).GenotypingEgfrallelesin
mouse calvarial osteoblastic cells harvested from Col-Cre Egfr
f/f
mice revealed that there are significant amounts of Egfr
f
remaining. However, further decreasing this residual EGFR
activity by introducing a dominant-negative Wa5 allele into
mice resulted in a strong bone phenotype, suggesting that EGFR
activity needs to be reduced to a very low level to affect bone
structures. EGFRs are expressed widely in cells of mesodermal
andectodermal originbut notincellsofhematopoietic origin.
(28)
While a complete knockdown of Egfr is embryonic lethal,
decreasing EGFR activity to a certain degree seems to have only
minoreffects. For example, Egfr
þ/– miceareviableand fertileand
behave virtually the same as Egfr
þ/þ mice. In vitro, equimolar
expression of Egfr and Egfr
wa5 in CHO cells results in less than
10% of wild-type phosphorylation of the EGFR, but in vivo, the
only significant phenotypes observed in Egfr
Wa5/þ mice are open
eyelids at birth and wavy coat.
(19) We did not observe any
trabecular or cortical bone abnormalities in Egfr
Wa5/þ mice.
Consistent with this, previous studies showed that total
volumetric BMD, cross-sectional area, and cortical thickness in
Egfr
Wa5/þ femurs were the same as in wild-type siblings.
(17)
Our conclusion that EGFR primarily plays an anabolic role in
bone metabolism is in agreement with other studies. Previous
data from our laboratory showed decreases in trabecular BMD
and bone volume but no change in cortical bone parameters in
amphiregulin knockout mice.
(5) In humeri of Egfr null mice, there
were fewer trabeculae than in wild-type mice at E18.5, and this
phenomenon persisted until birth.
(15) The most dramatic effect
of ubiquitous overexpression of BTC in mice (BTC-Tg) is high
cortical bone mass in femurs with increased cortical area and
thickness owing to augmented endocortical bone apposition.
(17)
This effect depends on the EGFR because it was blocked in the
Egfr
Wa5 background. These data are consistent with our findings
that EGFR activity is positively correlated with cortical bone size.
However, BTC-Tg mice showed profound increases in cortical
porosity, which was not observed in our mouse models. Another
discrepancy was the reduction of the vertebral BMD in BTC-Tg
mice. The femoral trabecular bone volume was higher only in
female transgenic mice at 6 weeks of age, but not in the males,
and this increase was not translated into higher trabecular BMD.
The difference described earlier could be due to high
nonphysiologic expression of BTC under the control of the
chicken b-actinpromoterintransgenicmice,andwebelievethat
our models are more accurate in revealing the osteoblastic EGFR
functions.
Histomorphometric analyses revealed decreased bone for-
mation and increased bone resorption in the EGFR-deficient
models and vice versa in the EGFR- augmented model. EGF-like
ligands have direct actions on osteoblast proliferation and
differentiation. EGF has been known for a long time as a mitogen
for both UMR 106-01cells, a rat osteosarcoma osteoblastic cell
line, and primary calvarial osteoblastic cells.
(29) In our past
studies, we demonstrated that amphiregulin has strong
proliferative effects on preosteoblasts and that EGFR signaling
is important for normal growth of osteoblastic cells. Osteoblasts
originate from mesenchymal stem cells, and EGF and HB-EGF are
important growth factors for maintaining their growth in
vitro.
(3,4) In vitro experiments also showed that activation of
EGFR strongly suppresses osteogenesis and particularly inhibits
bone marker genes such as alkaline phosphatase, type 1 collagen,
BSP, and osteocalcin
(5,30,31) and osteoblastic-specific transcription
factors Runx2 and osterix.
(6) Furthermore, studies of primary
calvarial osteoblastic cultures from EGFR-deficient mice, such as
Egfr
-/- mice, and humanized EGFR mice showed a decrease in
osteoblast proliferation and an increase in mineralization.
(16)
Interestingly, we found that the number and size of CFU-F
colonies from Col-Cre Egfr
Wa5/f mice were decreased in
comparison with wild-type mice when EGF-like ligands were
added to the culture medium, suggesting that these EGFR-
defective mice has fewer osteoprogenitors and that these
osteoprogenitors are less proliferative. Combining these in vitro
and in vivo mouse models data together, we hypothesize that
osteoblastic EGFR signalingmaintainsapool ofosteoprogenitors
and keeps these cells at an undifferentiated stage for future
osteogenesis stimulated by other factors.
To date, all in vitro data point out that EGFR signaling
enhances bone resorption by osteoclasts, although it is still
controversial whether EGF-like ligands act directly or indirectly
on osteoclasts. It has long been demonstrated that EGF
stimulates
45Ca release in fetal rat long bone cultures.
(8,32)
Gefitinib inhibits the ability of the MSC-like cell line HDS to
support osteoclastogenesis by suppressing the expression of M-
CSF and RANKL.
(33) Studies from our laboratory found that
osteoclasts do not bind [
125I]EGF and do not respond to EGF
treatment. Instead, EGF stimulates osteoclastogenesis in osteo-
blast/osteoclast cocultures by blocking the synthesis of OPG and
increasing the amount of MCP-1 produced by osteoblasts.
(10)
However, Yi and colleagues recently demonstrated that mouse
primary bone marrow osteoclast cultures do express EGFR
protein, as detected by Western blot and immunofluorescence.
Suppression of EGFR activity using an inhibitor or siRNA
interfered with the RANKL signaling and subsequently reduced
osteoclast differentiation.
(34) Hence we were surprised to
observe the negative correlation between EGFR activity and
bone resorption in our mouse models. It is possible that in vitro
experiments have used high doses of EGF and are more
reminiscent ofsituations where cancer cellswith high expression
levels of EGF-like ligands result in osteolytic lesions in bone.
(10,35)
Under physiological conditions, the expression of EGF-like
1032 Journal of Bone and Mineral Research ZHANG ET AL.ligands in bone may be low, and therefore, activating
osteoblastic EGFR activity actually decreases osteoclast forma-
tion and bone resorption. In addition, we found that there were
no difference in the Rankl/Opg mRNA ratio in the femoral
secondary spongiosa harvested from Col-Cre Egfr
Wa5/f and
Egfr
Dsk5/þ mice and their respective wild-type controls (data
not shown). Further experiments are required to address this
discrepancy between these in vitro and in vivo data.
In conclusion, our study demonstrates that osteoblastic EGFR
signaling primarily plays an anabolic role in bone metabolism,
implying its potential role in osteoporosis. This finding
establishes EGFR as an important signaling molecule in bone
development and remodeling and warrants further exploration
of EGFR as an anabolic drug target. It would be of interest to
study whether and how EGFR signaling engages other important
bone signaling pathways, such as BMP, Notch, and Wnt.
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